Temel İstatistikler
| LEI | 549300GB18Q03BWVIM19 |
| CIK | 1125440 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Internatural Pharmaceuticals Inc
SEC Filings (Chronological Order)
Bu sayfa, başka bir yerde sunduğumuz mülkiyet başvuruları hariç, SEC Dosyalarının tam ve kronolojik bir listesini sunmaktadır.
| December 4, 2006 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 15 UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 0-32889 INTERNATIONAL PHARMACEUTICALS, INC.. (Exact name of re |
|
| May 14, 2002 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 000-32889 CUSIP NUMBER: 46061X-10-6 (Check One): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form N-SAR For Period Ended: March 31, 2002 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 1 |
|
| April 15, 2002 |
1 (Form 10KSB) U.S. SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 - FORM 10-KSB - (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended 2001 -or- [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO. 0-29369 INTERNATURAL PHA |
|
| April 11, 2002 |
EX-7 3 ex71.txt EXHIBIT 7.1 1 (Exhibit 7.1) STOCK PURCHASE AGREEMENT WITH PROMISSORY NOTE This STOCK PURCHASE AGREEMENT WITH PROMISSORY NOTE (hereinafter referred to as the "Agreement") is entered into as of this 22nd day of March, 2002, by and between InterNatural Pharmaceuticals, Inc., a Nevada corporation (the "Buyer" or "Investor"); Coslabs, Ltd., H. Bana Ltd., and Overland Food Co. (collectiv |
|
| April 11, 2002 |
1 (Form 8-K) U.S. SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 - FORM 8-K - CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 - March 26, 2002 Date of Report (Date of earliest event reported) INTERNATURAL PHARMACEUTICALS, INC. - (Name of Small Business Issuer in its charter) Nevada 52-2265135 - - (State or other jurisdiction of (I.R.S. Employer incor |
|
| April 11, 2002 |
EX-7 5 ex73.txt EXHIBIT 7.3 1 (Exhibit 7.3) Trademark Assignment This Agreement is by and between Overland Food Co., a Delaware corporation ("Assignor") and Neurochemical Research Corporation, a Tennessee corporation ("Assignee"). WHEREAS, Assignor, is the owner of that trademarks identified as follows: a. Trim-A-Way, Registration No.1,780,004, issued on 7/6/93. b. QuitSystem, Registration No. 1,6 |
|
| April 11, 2002 |
EX-7 4 ex72.txt EXHIBIT 7.2 1 (Exhibit 7.2) STOCK EXCHANGE AGREEMENT This STOCK EXCHANGE AGREEMENT (hereinafter referred to as the "Agreement") entered into as of this 28th day of March, 2002, is by and between InterNatural Pharmaceuticals, Inc. (hereinafter referred to as "INAT") and Neurochemical Research Corp. (hereinafter referred to as "NRC"). WITNESSETH WHEREAS, INAT is a Nevada corporation |
|
| March 28, 2002 |
NT 10-K 1 inatnotice.txt NOTICE OF LATE FILING 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 - FORM 12b-25 - NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-32889 CUSIP NUMBER 46061X-10-6 (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form N-SAR For Period Ended: December 31, 2001 [ ] Transition Report on Form 10-K [ ] Transition Report on Form |
|
| February 6, 2002 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 - FORM 8-K - CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 - January 2, 2002 Date of Report (Date of earliest event reported) INTERNATURAL PHARMACEUTICALS, INC. - (Name of Small Business Issuer in its charter) Nevada 52-2265135 - - (State or other jurisdiction of (I.R.S. Employer incorporation or |
|
| November 21, 2001 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB Internatural Pharmaceuticals, Inc. Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2001. OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION |
|
| November 14, 2001 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 - FORM 12b-25 - NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-32889 CUSIP NUMBER 46061X-10-6 (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR For Period Ended: September 30, 2001 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Tra |
|
| November 6, 2001 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 - FORM 8-K - CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 - November 5, 2001 Date of Report (Date of earliest event reported) INTERNATURAL PHARMACEUTICALS, INC. - (Name of Small Business Issuer in its charter) Nevada 52-2265135 - - (State or other jurisdiction of (I.R.S. Employer incorporation or |
|
| October 31, 2001 |
Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 15, 2001 Date of Report (Date of earliest event reported) INTERNATURAL PHARMACEUTICALS, INC. (Name of Small Business Issuer in its charter) Nevada 52-2265135 (State or other jurisdiction of incorporation or organizati |
|
| September 28, 2001 |
1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB (Mark One) /X/ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2001. OR / / TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION FROM TO . COMMISSION FILE NUMBER 0-29369 INTERNATURAL PH |
|
| August 2, 2001 |
1 EXHIBIT 99.1 CERTIFICATE OF AMENDMENT OF ARTICLES OF INCORPORATION (After Issuance of Stock) Filed by: FILED# C7360-96 JUL 13 2001 IN THE OFFICE OF /s/ DEAN HELLER DEAN HELLER, SECRETARY OF STATE CHECKPOINT GENETICS PHARMACEUTICALS, INC. - Name of Corporation We the undersigned LUCILLE V. ABAD, President - President or Vice President ROY RAYO, Assistant Secretary of CHECKPOINT GENETICS PHARMACEU |
|
| August 2, 2001 |
Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 31, 2001 INTERNATURAL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 000-32889 52-2265135 (State or other jurisdiction of incorporation) |
|
| June 15, 2001 |
1 BY-LAWS OF CHECKPOINT GENETICS PHARMACEUTICALS, INC. ARTICLE I OFFICES Section 1. PRINCIPAL OFFICE. The principal office for the transaction of business of the corporation shall be fixed or may be changed by approval of a majority of the authorized Directors, and additional offices may be established and maintained at such other place or places as the Board of Directors may from time to time des |
|
| June 15, 2001 |
1 EXHIBIT 3.3 FILED #C7360-96 AUGUST 23, 2000 IN THE OFFICE OF /s/ DEAN KELLER DEAN KELLER SECRETARY OF STATE CERTIFICATE OF AMENDMENT OF ARTICLES OF INCORPORATION OF LABCO PHARMACEUTICALS CORPORATION (After Issuance of Stock) I, the undersigned sole officer of Labco Pharmaceuticals Corporation, a Nevada corporation, do hereby certify: 1. That the Sole Director of said corporation, on August 15, 2 |
|
| June 15, 2001 |
10SB12G 1 v73516e10sb12g.txt FORM 10SB 1 U.S. SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 - FORM 10-SB - GENERAL FORM FOR REGISTRATION OF SECURITIES OF SMALL BUSINESS ISSUERS Under Section 12(g) of The Securities Exchange Act of 1934 - CHECKPOINT GENETICS PHARMACEUTICALS, INC. - (Name of Small Business Issuer in its charter) Nevada 52-2265135 - - (State or other jurisdiction of (I.R.S |
|
| June 15, 2001 |
1 EXHIBIT 3.2 FILED IN THE OFFICE OF THE SECRETARY OF STATE OF THE STATE OF NEVADA APR 23 1996 DEAN HELLER SECRETARY OF STATE /s/ Dean Heller No. 7360-96 ARTICLES OF MERGER OF PARKSIDE INDUSTRIES, INC. (A UTAH CORPORATION) INTO PARKSIDE INDUSTRIES, INC. (A NEVADA CORPORATION) The undersigned officers, president and assistant secretary of Parkside Industries, Inc., a Utah corporation, and Parkside |
|
| June 15, 2001 |
1 EXHIBIT 3.1 FILED WITH THE OFFICE OF THE SECRETARY OF STATE OF THE STATE OF NEVADA APR 2 1996 NO. 7360-96 /s/ DEAN HELLER Dean Heller, Secretary of State ARTICLES OF INCORPORATION OF PARKSIDE INDUSTRIES INC. The undersigned persons of the age of twenty one or more, acting as incorporators under the general corporation law (Chapter 78 of the Nevada revised Statutes) of the State of Nevada, do her |
|
| June 15, 2001 |
EX-21 7 v73516ex21.txt EXHIBIT 21 1 LIST OF SUBSIDIARIES Checkpoint Genetics Group, Inc 4201 Wilshire Boulevard, Suite 525 Los Angeles, California 90010 Tel. No. (323) 954-9808 Checkpoint Genetics Inc. 1195 McDermott Drive West Chester, PA 19380 Tel. No. (610) 696-3730 |
|
| June 15, 2001 |
EX-4 6 v73516ex4.txt EXHIBIT 4 1 EXHIBIT 4 "LEGEND ON REVERSE SIDE" NOT VALID UNLESS COUNTERSIGNED BY TRANSFER AGENT INCORPORATED UNDER THE LAWS OF THE STATE OF NEVADA NUMBER SHARES 6348 ***5,000,000*** CUSIP NO. 162822 10 0 CHECKPOINT GENETICS PHARMACEUTICALS, INC. RESTRICTED STOCK AUTHORIZED COMMON STOCK: 140,000,000 SHARES PAR VALUE: $.001 This Certifies that ***RIDGEWAY COMMERCIAL HOLDINGS LIM |
